Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | NQO2 | P16083 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30783436 | 1.00 | KCNA3 (0.61) | KCNA3KDM4ENQO2HSD17B10SMN1; SMN2 | |
| SCHEMBL1685959 | 0.81 | KCNA3 (0.57) | KCNA3KDM4ENQO2HSD17B10SMN1; SMN2 | |
| SCHEMBL11375444 | 0.81 | KCNA3 (0.69) | KCNA3KDM4ENQO2HSD17B10SMN1; SMN2 | |
| SCHEMBL29206051 | 0.80 | KCNA3 (0.56) | KCNA3KDM4ENQO2HSD17B10SMN1; SMN2 | |
| SCHEMBL11389662 | 0.79 | KCNA3 (0.74) | KCNA3SMN1; SMN2ALDH1A1GAAHPGD | |
| SCHEMBL17576252 | 0.79 | KDM4E (0.49) | KCNA3KDM4ENQO2HSD17B10SMN1; SMN2 | |
| SCHEMBL12002308 | 0.78 | ALDH1A1 (0.66) | KDM4ESMN1; SMN2ALDH1A1HPGDMAPT | |
| SCHEMBL19330830 | 0.78 | MAPT (0.55) | KDM4ENQO2HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL18026627 | 0.78 | KCNA3 (0.64) | KCNA3KDM4ENQO2HSD17B10SMN1; SMN2 | |
| SCHEMBL2797897 | 0.78 | ALDH1A1 (0.51) | KDM4ESMN1; SMN2ALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-03-29 | — | — | US | claimed |
| US-20210147364-A1 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-05-20 | — | — | US | claimed |
| US-20250032448-A1 | COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES | KOH, Hwee Ling (SG) | 2025-01-30 | — | — | US | disclosed |
| US-12144797-B2 | Compound for use in the treatment and/or prevention of parasitic mediated diseases | KOH, Hwee Ling (SG) | 2024-11-19 | — | — | US | disclosed |
| CN-117624043-A | Preparation method of quinolinone compound | 安徽中医药大学 | 2024-03-01 | — | — | CN | disclosed |
| EP-4227304-A2 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | Novartis AG (CH) | 2023-08-16 | — | — | EP | disclosed |
| EP-3736271-B1 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-03-29 | — | — | US | disclosed |
| US-20210147364-A1 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-05-20 | — | — | US | disclosed |
| EP-3736271-A1 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | Novartis AG (CH) | 2020-11-11 | — | — | EP | disclosed |
| EP-3389649-B1 | FURANOCOUMARINS FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES | LEEWARD PACIFIC PTE LTD (SG) | 2020-10-21 | — | — | EP | disclosed |
| WO-2014144606-A2 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140206661-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | NOVARTIS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| EP-2727594-A1 | NOVEL PHARMACEUTICAL COMPOSITION | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-05-07 | — | — | EP | disclosed |
| WO-2014040077-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSISITY OF NEVADA, RENO (US) | 2014-03-13 | — | — | WO | disclosed |
| US-20140072536-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072536-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) | 2014-03-13 | — | — | US | disclosed |
| US-4273930-A | INTERMEDIATES FOR THE 4-ALKOXY ANTIALLERGENS | SANDOZ, INC. (US) | 1981-06-16 | — | — | US | disclosed |
| US-4190659-A | ANTIALLERGENS, ANTIHISTAMINES | SANDOZ, INC. (US) | 1980-02-26 | — | — | US | disclosed |
| US-4032528-A | DEPRESSANTS | SANDOZ, INC. (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144797-B2 | Compound for use in the treatment and/or prevention of parasitic mediated diseases | ICMT, ALG3, PFN1 | KCNA3 425/4885KDM4E 2090/4885NQO2 1300/4885 |
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | CBR1, POR, CAT | KCNA3 2807/4885KDM4E 3025/4885NQO2 243/4885 |
| US-20210147364-A1 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | CBR1, POR, CAT | KCNA3 2384/4885KDM4E 3242/4885NQO2 259/4885 |
| US-20250032448-A1 | COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES | EPX, PKD2, MPO | KCNA3 946/4885KDM4E 2625/4885NQO2 1449/4885 |
| US-20140072536-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | KCNA3 3139/4885KDM4E 3012/4885NQO2 1189/4885 |
| US-20140206661-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | SMN1; SMN2, SF3B5, SF3B1 | KCNA3 2452/4885KDM4E 2739/4885NQO2 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.